Your browser is no longer supported. Please, upgrade your browser.
DVA DaVita Inc. monthly Stock Chart
DaVita Inc.
IndexS&P 500 P/E13.73 EPS (ttm)6.29 Insider Own2.20% Shs Outstand122.08M Perf Week-3.73%
Market Cap10.83B Forward P/E11.53 EPS next Y7.49 Insider Trans-45.82% Shs Float118.34M Perf Month2.53%
Income823.60M PEG1.25 EPS next Q1.44 Inst Own92.20% Short Float4.08% Perf Quarter-5.32%
Sales11.52B P/S0.94 EPS this Y28.30% Inst Trans-1.91% Short Ratio4.40 Perf Half Y9.19%
Book/sh17.64 P/B4.89 EPS next Y9.25% ROA4.60% Target Price97.80 Perf Year46.34%
Cash/sh24.56 P/C3.51 EPS next 5Y11.00% ROE38.80% 52W Range57.92 - 92.67 Perf YTD14.98%
Dividend- P/FCF6.57 EPS past 5Y6.60% ROI13.00% 52W High-7.19% Beta1.20
Dividend %- Quick Ratio1.30 Sales past 5Y-2.30% Gross Margin31.00% 52W Low48.49% ATR2.25
Employees65000 Current Ratio1.40 Sales Q/Q1.30% Oper. Margin14.70% RSI (14)43.40 Volatility1.88% 2.65%
OptionableYes Debt/Eq4.55 EPS Q/Q39.60% Profit Margin7.20% Rel Volume0.74 Prev Close86.27
ShortableYes LT Debt/Eq3.67 EarningsOct 29 AMC Payout0.00% Avg Volume1.10M Price86.01
Recom2.70 SMA20-2.50% SMA50-1.51% SMA2005.26% Volume716,063 Change-0.30%
Jan-24-20Upgrade Goldman Neutral → Buy $72 → $97
Nov-07-19Downgrade Raymond James Outperform → Mkt Perform
Oct-25-19Downgrade Wolfe Research Outperform → Peer Perform
Sep-11-19Downgrade William Blair Outperform → Mkt Perform
Jul-26-19Downgrade Robert W. Baird Outperform → Neutral $70 → $65
Jan-08-19Upgrade UBS Sell → Neutral
Jan-03-19Initiated Deutsche Bank Buy $60
Dec-14-18Initiated Barclays Overweight
Nov-28-18Upgrade Raymond James Mkt Perform → Outperform
Nov-16-18Initiated UBS Sell $64
Nov-08-18Downgrade Raymond James Strong Buy → Mkt Perform
Sep-13-18Upgrade JP Morgan Underweight → Neutral
Jan-04-18Upgrade BofA/Merrill Neutral → Buy
Dec-12-17Upgrade Robert W. Baird Neutral → Outperform $63 → $82
Dec-11-17Upgrade Citigroup Neutral → Buy
Dec-07-17Upgrade Raymond James Outperform → Strong Buy
Nov-08-17Reiterated RBC Capital Mkts Sector Perform $64 → $60
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Jun-26-17Downgrade Jefferies Buy → Hold
Dec-13-16Downgrade Robert W. Baird Outperform → Neutral $68 → $69
Oct-28-20 12:26PM  
Oct-26-20 11:50AM  
Oct-22-20 12:34PM  
Oct-21-20 11:40AM  
Oct-20-20 08:01AM  
Oct-19-20 08:49AM  
Oct-15-20 04:52PM  
Oct-14-20 09:23AM  
Oct-13-20 08:37AM  
Oct-09-20 11:50AM  
Oct-08-20 11:30AM  
Oct-07-20 07:56AM  
Oct-05-20 11:40AM  
Oct-01-20 09:58AM  
Sep-27-20 09:44AM  
Sep-26-20 10:30AM  
Sep-25-20 01:52PM  
Sep-24-20 08:48AM  
Sep-23-20 11:50AM  
Sep-22-20 01:16PM  
Sep-21-20 01:33PM  
Sep-18-20 11:40AM  
Sep-17-20 09:15AM  
Sep-16-20 06:27PM  
Sep-15-20 06:30AM  
Sep-10-20 10:11AM  
Sep-09-20 08:33AM  
Sep-08-20 02:04PM  
Sep-07-20 11:50AM  
Aug-31-20 08:05AM  
Aug-29-20 11:31AM  
Aug-27-20 04:07PM  
Aug-24-20 07:14PM  
Aug-21-20 11:47AM  
Aug-20-20 11:50AM  
Aug-19-20 11:40AM  
Aug-17-20 06:16AM  
Aug-13-20 01:18PM  
Aug-11-20 04:30AM  
Aug-06-20 06:01PM  
Aug-04-20 11:50AM  
Aug-03-20 11:40AM  
Jul-31-20 12:14PM  
Jul-30-20 05:35PM  
Jul-27-20 07:14AM  
Jul-23-20 12:33PM  
Jul-16-20 02:18PM  
Jul-15-20 04:01PM  
Jul-10-20 07:19AM  
Jul-09-20 09:48AM  
Jul-08-20 11:40AM  
Jul-07-20 11:30AM  
Jul-06-20 08:15PM  
Jul-03-20 08:26AM  
Jun-23-20 12:39PM  
Jun-17-20 06:17AM  
Jun-16-20 12:20PM  
Jun-11-20 09:19AM  
Jun-10-20 11:40AM  
Jun-04-20 10:32AM  
Jun-02-20 09:24PM  
May-29-20 07:37PM  
May-28-20 06:17AM  
May-26-20 06:05PM  
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2019, it provided dialysis and administrative services in the United States through a network of 2,753 outpatient dialysis centers serving approximately 206,900 patients; and operated 259 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 28,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEHRA JOHN MDirectorSep 23Buy82.952,500207,3745,500Sep 24 06:22 PM
NEHRA JOHN MDirectorSep 22Buy84.603,000253,8143,000Sep 24 06:22 PM
ZUMWALT LEANNE MGroup VP, Government AffairsSep 18Option Exercise72.6036,9232,680,72151,049Sep 22 07:59 PM
ZUMWALT LEANNE MGroup VP, Government AffairsSep 18Sale88.033,772332,03124,590Sep 22 07:59 PM
WESCHLER, R. TEDMember of 10% owner groupSep 17Sale88.002,000,000176,000,00036,095,570Sep 21 04:38 PM
WESCHLER, R. TEDMember of 10% owner groupSep 17Sale88.00200,00017,600,0001,991,806Sep 21 04:38 PM
Arway Pamela MDirectorAug 24Sale87.0257850,29819,239Aug 25 05:56 PM
BERG CHARLESDirectorJun 08Option Exercise81.514,662380,00015,666Jun 10 06:21 PM
DIAZ PAUL JDirectorJun 08Option Exercise81.514,662380,00010,598Jun 10 06:22 PM
ROPER WILLIAM LDirectorJun 08Option Exercise81.514,662380,00020,623Jun 10 06:21 PM
Arway Pamela MDirectorJun 08Option Exercise81.514,662380,00023,901Jun 10 06:21 PM
NEHRA JOHN MDirectorJun 08Option Exercise81.514,662380,0004,662Jun 10 06:22 PM
GRAUER PETER TDirectorJun 08Option Exercise71.1935,0832,497,46883,790Jun 10 06:23 PM
Arway Pamela MDirectorJun 08Sale87.3235731,17419,239Jun 10 06:21 PM
ROPER WILLIAM LDirectorJun 08Sale86.7935730,98315,961Jun 10 06:21 PM
BERG CHARLESDirectorJun 08Sale87.5335731,24911,004Jun 10 06:21 PM
Arway Pamela MDirectorMay 22Sale78.9059947,26119,239May 27 04:05 PM
DIAZ PAUL JDirectorMay 18Sale82.225,763473,8259,986May 19 09:19 PM
THIRY KENT JExecutive ChairmanMay 12Sale80.8962,0005,015,000548,653May 13 08:47 PM
THIRY KENT JExecutive ChairmanMay 11Option Exercise75.42145,52210,975,269283,369May 13 08:47 PM
THIRY KENT JExecutive ChairmanMay 11Sale81.2862,0005,039,391610,653May 13 08:47 PM
THIRY KENT JExecutive ChairmanMay 11Sale81.185,390437,537137,847May 13 08:47 PM
Arway Pamela MDirectorMar 20Sale71.2562544,53119,239Mar 24 06:42 PM
NEHRA JOHN MDirectorMar 02Sale80.747,694621,21454,759Mar 04 07:11 PM
NEHRA JOHN MDirectorFeb 27Sale80.4911,806950,26562,453Feb 28 07:07 PM
NEHRA JOHN MDirectorFeb 26Sale80.9320,0001,618,60074,259Feb 28 07:07 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.